CRBU Caribou Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRBU

Price (delayed)

$2.065

Market cap

$204.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.42

Enterprise value

$219.7M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 32
Highlights
Caribou Biosciences's EPS has increased by 12% YoY and by 11% QoQ
Caribou Biosciences's net income has increased by 10% QoQ and by 10% YoY
CRBU's gross profit is down by 21% from the previous quarter but it is up by 16% YoY
The revenue has declined by 21% since the previous quarter but it has increased by 16% year-on-year
The equity has shrunk by 53% YoY and by 16% QoQ
Caribou Biosciences's debt has increased by 2.8% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CRBU

CRBU stock price

How has the Caribou Biosciences stock price performed over time
Intraday
3.25%
1 week
-10.61%
1 month
8.12%
1 year
82.74%
YTD
29.87%
QTD
8.68%

Financial performance

How have Caribou Biosciences's revenue and profit performed over time
Revenue
$8.81M
Gross profit
$8.81M
Operating income
-$134.11M
Net income
-$133.22M
Gross margin
100%
Net margin
-1,512.8%
The company's operating margin rose by 31% YoY but it fell by 15% QoQ
Caribou Biosciences's net margin has increased by 23% YoY but it has decreased by 14% from the previous quarter
CRBU's gross profit is down by 21% from the previous quarter but it is up by 16% YoY
The revenue has declined by 21% since the previous quarter but it has increased by 16% year-on-year

Price vs fundamentals

How does CRBU's price correlate with its fundamentals

Growth

What is Caribou Biosciences's growth rate over time

Valuation

What is Caribou Biosciences stock price valuation
P/E
N/A
P/B
1.96
P/S
22.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.95
Caribou Biosciences's EPS has increased by 12% YoY and by 11% QoQ
The equity has shrunk by 53% YoY and by 16% QoQ
The P/B is 45% more than the 5-year quarterly average of 1.3 and 45% more than the last 4 quarters average of 1.3
CRBU's P/S is 24% below its 5-year quarterly average of 28.8 but 5% above its last 4 quarters average of 20.7
The revenue has declined by 21% since the previous quarter but it has increased by 16% year-on-year

Efficiency

How efficient is Caribou Biosciences business performance
The ROE has plunged by 80% YoY and by 9% from the previous quarter
CRBU's ROA has dropped by 59% year-on-year and by 5% since the previous quarter
CRBU's return on invested capital has dropped by 55% year-on-year and by 2.8% since the previous quarter
Caribou Biosciences's return on sales has increased by 22% YoY but it has decreased by 14% QoQ

Dividends

What is CRBU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRBU.

Financial health

How did Caribou Biosciences financials performed over time
The company's total assets fell by 46% YoY and by 15% QoQ
The current ratio has contracted by 18% YoY but it has grown by 9% from the previous quarter
Caribou Biosciences's debt is 74% less than its equity
Caribou Biosciences's debt to equity has soared by 117% YoY and by 18% from the previous quarter
The equity has shrunk by 53% YoY and by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.